These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 26198340)
1. Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. Cremin I; Morales F; Jewell BL; O'Reilly KR; Hallett TB J Int AIDS Soc; 2015; 18(4 Suppl 3):19946. PubMed ID: 26198340 [TBL] [Abstract][Full Text] [Related]
2. Willingness to use short-term oral pre-exposure prophylaxis (PrEP) by migrant miners and female partners of migrant miners in Mozambique. Falcao J; Ahoua L; Zerbe A; di Mattei P; Baggaley R; Chivurre V; Mulondo P; Ramiro I; Dalal S; Morales F; O'Reilly K; El-Sadr W Cult Health Sex; 2017 Dec; 19(12):1389-1403. PubMed ID: 28468533 [TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique. Falcao J; Zerbe A; Lahuerta M; Baggaley R; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM AIDS Patient Care STDS; 2017 Dec; 31(12):528-534. PubMed ID: 29211515 [TBL] [Abstract][Full Text] [Related]
4. Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique. Lahuerta M; Zerbe A; Baggaley R; Falcao J; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM J Acquir Immune Defic Syndr; 2017 Dec; 76(4):343-347. PubMed ID: 28777264 [TBL] [Abstract][Full Text] [Related]
5. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512 [TBL] [Abstract][Full Text] [Related]
6. Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis. Stelzle D; Godfrey-Faussett P; Jia C; Amiesimaka O; Mahy M; Castor D; Hodges-Mameletzis I; Chitembo L; Baggaley R; Dalal S PLoS Med; 2021 Jan; 18(1):e1003482. PubMed ID: 33428611 [TBL] [Abstract][Full Text] [Related]
7. Pre-exposure prophylaxis use among HIV serodiscordant couples: a qualitative study in Mozambique. Sack DE; De Schacht C; Paulo P; Graves E; Emílio AM; Matino A; Fonseca CL; Aboobacar AU; Van Rompaey S; Audet CM Glob Health Action; 2021 Jan; 14(1):1940764. PubMed ID: 34229580 [TBL] [Abstract][Full Text] [Related]
8. HIV Susceptibility Among Migrant Miners in Chokwe: A Case Study. Martins-Fonteyn E; Loquiha O; Wouters E; Raimundo I; Hens N; Aerts M; Meulemans H Int J Health Serv; 2016 Oct; 46(4):712-33. PubMed ID: 25995302 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis. Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959 [TBL] [Abstract][Full Text] [Related]
10. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Verguet S; Stalcup M; Walsh JA Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502 [TBL] [Abstract][Full Text] [Related]
12. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V; Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378 [TBL] [Abstract][Full Text] [Related]
14. Perceptions of Pre-exposure Prophylaxis (PrEP) for HIV prevention among men living with HIV in the context of reproductive goals in South Africa: a qualitative study. Ntinga X; Isehunwa OO; Msimango LI; Smith PM; Matthews LT; Van Heerden A BMC Public Health; 2024 Feb; 24(1):553. PubMed ID: 38389039 [TBL] [Abstract][Full Text] [Related]
15. "Emotional stress is more detrimental than the virus itself": A qualitative study to understand HIV testing and pre-exposure prophylaxis (PrEP) use among internal migrant men in South Africa. Nardell MF; Govathson-Mandimika C; Garnier S; Watts A; Babalola D; Ngcobo N; Long L; Lurie MN; Miot J; Pascoe S; Katz IT J Int AIDS Soc; 2024 Mar; 27(3):e26225. PubMed ID: 38462755 [TBL] [Abstract][Full Text] [Related]
16. Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. Bazzi AR; Leech AA; Biancarelli DL; Sullivan M; Drainoni ML AIDS Patient Care STDS; 2017 Aug; 31(8):348-355. PubMed ID: 28719229 [TBL] [Abstract][Full Text] [Related]
17. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. Hallett TB; Baeten JM; Heffron R; Barnabas R; de Bruyn G; Cremin Í; Delany S; Garnett GP; Gray G; Johnson L; McIntyre J; Rees H; Celum C PLoS Med; 2011 Nov; 8(11):e1001123. PubMed ID: 22110407 [TBL] [Abstract][Full Text] [Related]
18. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240 [TBL] [Abstract][Full Text] [Related]
19. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205 [TBL] [Abstract][Full Text] [Related]
20. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]